Last updated: April 6, 2024
Sponsor: Suleyman Demirel University
Overall Status: Active - Not Recruiting
Phase
3
Condition
Heart Disease
Coronary Artery Disease
Cardiac Disease
Treatment
NAC
Saline
Clinical Study ID
NCT01878344
ozaydin290
Ages 18-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with Acute ST Elevation Myocardial Infarction undergoing Primary PercutaneousCoronary intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy (Mehran Score ≥5)
Exclusion
Exclusion Criteria:
- Patients >18 years old with moderate to high risk for contrast induced nephropathyundergoing percutaneous coronary intervention
- Low risk for contrast induced nephropathy (Mehran Score <5)
- Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...)
- Infection
- Pregnancy, Lactation
- Renal failure requiring dialysis
- Hepatic failure
- Allergy to NAC
- History of Asthma
- Chronic nitrate usage
- Malignancy
- Use of corticosteroids
- Leucocytosis,Thrombocytosis,Anemia
- Blood pressure of >180/100mmHg despite anti-hypertensive therapy
Study Design
Total Participants: 100
Treatment Group(s): 2
Primary Treatment: NAC
Phase: 3
Study Start date:
January 01, 2013
Estimated Completion Date:
December 31, 2024
Connect with a study center
Suleyman Demirel University
Isparta, Mediterranean Region 32260
TurkeySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.